Merck grows Keytruda indications with head and neck cancer approval
Merck’s checkpoint star is shining a little brighter today with two new approvals in head and neck squamous cell carcinoma.
The pharma giant first clinched an accelerated approval to use Keytruda in recurrent or metastatic cases in 2016, targeting patients whose disease progressed on or after platinum-based chemotherapy.
On Tuesday the FDA converted it into a full approval right at the end of a priority review period, and additionally stamped its OK on Keytruda as a frontline treatment for head and neck cancer. That covers both monotherapy (in patients whose tumor express PD-L1) and a combination with platinum and fluorouracil, or FU (whole population).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.